Curated News
By: NewsRamp Editorial Staff
July 02, 2025
Nutriband Announces 25% Preferred Stock Dividend Ahead of AVERSA Fentanyl FDA Approval
TLDR
- Nutriband's 25% preferred stock dividend offers shareholders a strategic advantage, converting to common shares upon FDA approval of AVERSA Fentanyl, enhancing investment value.
- Nutriband will issue one preferred share for every four common shares held by July 25, 2025, convertible to common shares post-FDA approval of AVERSA Fentanyl.
- Nutriband's AVERSA technology aims to reduce drug abuse, making communities safer by preventing misuse of transdermal patches with abuse potential.
- Discover how Nutriband's innovative AVERSA technology transforms transdermal patches into safer alternatives, with a unique stock dividend opportunity for investors.
Impact - Why it Matters
This news is significant for investors and the pharmaceutical industry as it highlights Nutriband's innovative approach to preventing drug abuse through its AVERSA technology. The announcement of a preferred stock dividend reflects the company's confidence in its product pipeline and its commitment to shareholder value, marking a pivotal step towards the commercialization of a potentially life-saving technology. For stakeholders, this represents not just an investment opportunity but a chance to be part of a solution addressing the critical issue of drug abuse.
Summary
Nutriband Inc. (NASDAQ: NTRB), a company at the forefront of developing transdermal pharmaceutical products, has announced a significant move to enhance shareholder value. The Board of Directors has approved a 25% preferred stock dividend, offering one preferred share for every four common shares held by July 25, 2025, with distribution scheduled for August 5. This strategic decision is tied to the FDA approval of Nutriband's innovative AVERSA Fentanyl product, with each preferred share convertible to one common share upon approval. In the absence of conversion, these shares will be eligible for annual cash dividends, subject to the Board's discretion. CEO Gareth Sheridan highlighted this initiative as a testament to the company's dedication to its shareholders and its progress towards the commercialization of AVERSA, a groundbreaking abuse-deterrent technology designed to prevent the misuse of drugs with abuse potential.
For those interested in delving deeper into Nutriband's developments and its AVERSA technology, more information is available on their official website and through the full report linked in the announcement. This move not only underscores Nutriband's commitment to innovation in the pharmaceutical sector but also signals a promising future for investors and stakeholders alike.
Source Statement
This curated news summary relied on content disributed by InvestorBrandNetwork (IBN). Read the original source here, Nutriband Announces 25% Preferred Stock Dividend Ahead of AVERSA Fentanyl FDA Approval
